Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Exploring the use of olaparib in advanced breast cancer

Gaia Griguolo • 21 May 2020
ESMO Breast 2020
Breast Cancer Olaparib
OlympiAD

Gaia Griguolo, MD, of the Istituto Oncologico Veneto, Padua, Italy, discusses the use of olaparib in advanced breast cancer. The OlympiAD trial (NCT02000622) compared the use of olaparib against standard treatment in metastatic triple-negative breast cancer (TNBC) or HER2+ refractory patients and showed an improvement in progression free survival and an increased overall survival in TNBC subgroups. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Gaia Griguolo

2:09
HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BC
Gaia Griguolo • 7 Dec 2022
0:53
The latest news on the management of breast cancer patients with brain metastases
Gaia Griguolo • 7 Dec 2022
1:35
Gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes
Gaia Griguolo • 7 Dec 2022
1:19
Gene expression assays to identify patients with breast cancer for neoadjuvant treatment
Gaia Griguolo • 3 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals